Copyright: ©Author(s) 2026.
World J Orthop. May 18, 2026; 17(5): 116525
Published online May 18, 2026. doi: 10.5312/wjo.v17.i5.116525
Published online May 18, 2026. doi: 10.5312/wjo.v17.i5.116525
Table 2 Univariate analysis of the overall survival
| Characteristics | n | Median OS | 95%CI | P value |
| Age | 0.19 | |||
| > 70 | 15 | 5 | 1-15 | |
| < 71 | 9 | 10 | 4 to not censored | |
| Sex | 0.67 | |||
| Male | 11 | 6 | 2-15 | |
| Female | 13 | 7 | 1 to not censored | |
| Type of cancer | 0.020 | |||
| Low growth | 11 | 29 | 1 to not censored | |
| Moderate or rapid growth | 13 | 6 | 2-9 | |
| Surgical method | 0.0040 | |||
| Osteosynthesis | 17 | 6 | 1-9 | |
| Artificial head replacement | 7 | 77 | 4 to not censored | |
| Type of systemic treatment before surgery | 0.064 | |||
| Hormone therapy | 6 | 29 | 1 to not censored | |
| Anticancer drugs and/or molecularly targeted drugs | 18 | 5 | 3-9-not censored | |
| Visceral metastasis | 0.017 | |||
| Yes | 14 | 6 | 1-7 | |
| No | 10 | 15 | 1 to not censored | |
| Number of bone metastases | 0.94 | |||
| 1 | 6 | 9 | 1 to not censored | |
| Multiple | 18 | 6 | 4-29 | |
| Pathological fractures | 0.153 | |||
| Yes | 6 | 9 | 4 to not censored | |
| No | 18 | 6 | 2-15 | |
| Systemic treatment after surgery | 0.0030 | |||
| Yes | 14 | 29 | 5 to not censored | |
| No | 10 | 4 | 1-6 | |
| Albumin | 0.057 | |||
| ≥ 3.7 | 13 | 15 | 3 to not censored | |
| < 3.7 | 11 | 6 | 1-7 | |
| CRP | 0.867 | |||
| > 0.4 | 16 | 7 | 4-29 | |
| ≤ 0.4 | 8 | 5 | 1 to not censored | |
| LDH | 0.58 | |||
| ≥ 250 | 11 | 6 | 1-28 | |
| < 250 | 13 | 7 | 3 to not censored | |
- Citation: Ishibashi Y, Nakazato K, Tachibana N, Yu J, Ugawa S, Asanuma Y, Kusunoki Y, Hasebe S, Takahashi T, Hara N. Prognostic factors for patients undergoing surgery for femur metastases following systemic treatment. World J Orthop 2026; 17(5): 116525
- URL: https://www.wjgnet.com/2218-5836/full/v17/i5/116525.htm
- DOI: https://dx.doi.org/10.5312/wjo.v17.i5.116525